The Qb‐VLP has been administered in clinical trials for other indications, for example conjugated to a peptide from angiotensin II for treatment of hypertension (CYT006‐AngQb) 44 or conjugated with a nicotine‐like hapten for smoking cessation (CYT002‐NicQb) 45, 46. The gene discussed is AGT; the disease is Hypertension.